[Acute prostatism associated with milnacipran therapy: a case report].
Milnacipran is a dual serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor. Milnacipran is an orally administered drug and indicated for the treatment of major depressive disorder. It is a safe and well tolerated drug for use in daily clinical practice. Prostatism; a symptom complex resulting from compression or obstruction of the urethra symptoms include diminution in the calibre and force of the urinary stream, hesitancy in initiating voiding, inability to terminate micturition abruptly, sensation of incomplete bladder emptying and rarely urinary retention. A 38 year old male patient with major depression was prescribed milnacipran 25 mg bid. Within 24 hours after with the second dose the patient developed hesitancy in initiating voiding, intermittency, terminal dribbling, projection disability, calibration disability and incomplete emptying. Due to these side effects patient has discontinued the drug. These side effects regress and disappeared within 24 hours. He had no past and familial history of any illness. Since there was neither a concomitant medication nor a medical illness, in addition to the absence of physical, laboratory and radiological evidence of a possible cause for acute prostatism an association between milnacipran was suggested. In this report, we identify clinical characteristics of milnacipran induced acute prostatism. Physicians should be aware of this possible adverse effect. Patients should be informed about these signs and symptoms. Although milnacipran may cause on urinary complaints, this side effect may be useful for patients urine incontinence.